This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
MRI is particularly valuable in pediatric care due to its non-invasive nature
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Subscribe To Our Newsletter & Stay Updated
